< Back to previous page
Researcher
Arthur Van Aerschot
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Bioinformatics and computational biology
Affiliations
- Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 10 of 19
- Crystallographic facility for target-based drug designFrom1 May 2020 → TodayFunding: FWO International research infrastructure (IRI)
- Development of new antimicrobials: Rational design of polyomavirus and mycobacterial inhibitorsFrom1 Oct 2019 → 23 Nov 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development of a comprehensive platform for targeting redox homeostasis in Mycobacterium tuberculosis.From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Structure-guided design and development of antivirals targeting BK polyomavirus capsidFrom1 Oct 2018 → 30 Sep 2023Funding: IOF - Industrial Research Fund, Fund Recuperation Fiscal Exemption, BOF - Concerted Research Project from 1994
- Tyrosine-tRNA synthetase as target for the development of new antibacterial lead structuresFrom1 Sep 2018 → 1 Sep 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- In vivo molecular ion channel imaging.From1 May 2018 → 30 Sep 2022Funding: FWO Odysseus
- Structure-based design of new antitubercular medicinesFrom1 Oct 2017 → 30 Sep 2019Funding: BOF - Bilateral scientific cooperation
- Structural Characterization of Aminoacyl-tRNA Synthetase Inhibitors as Antibiotics and Tools for Enzyme Mechanistic StudiesFrom1 Oct 2016 → 23 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
- High throughput analysis of biomolecular interactionsFrom1 May 2016 → 30 Apr 2020Funding: FWO Medium Size Research Infrastructure
- Synthesis and biological evaluation of albomycin and aminoacyl sulfonamide analogues as potential aaRS inhibitors.From1 Oct 2015 → 30 Sep 2018Funding: FWO fellowships
Publications
81 - 90 of 98
- Patient experiences of over-the-counter medicine purchases in Flemish community pharmacies(2009)
Authors: Steven Simoens, Arthur Van Aerschot
Pages: 450 - 457 - Antimicrobial resistance in bacteria(2009)
Authors: Katrijn Bockstael, Arthur Van Aerschot
Pages: 141 - 155 - Detection of RNA Hybridization by Pyrene-Labeled Probes(2009)
Authors: Arthur Van Aerschot, Jef Rozenski, Mark Van der Auweraer, Piet Herdewyn, Steven De Feyter
Pages: 1175 - 1185 - A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity(2009)
Authors: Mikhail Abramov, Arthur Van Aerschot, Puneet Srivastava, Piet Herdewyn
Pages: 2867 - 2881 - Maturation of the Translation Inhibitor Microcin C(2009)
Authors: Gaston Vondenhoff, Arthur Van Aerschot
Pages: 2380 - 2387 - Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf(2009)
Authors: Mikhail Abramov, Arthur Van Aerschot, Jef Rozenski, Piet Herdewyn
Pages: 38 - 44 - Analysis of Dideoxyadenosine Triphosphate by Capillary Electrophoresis with Fluorescence Detection. Derivatization Through the Adenine Group(2009)
Authors: Swapna Mallampati, Arthur Van Aerschot, Jos Hoogmartens, Ann Van Schepdael
Pages: 2642 - 2653 - Synthesis and Base Pairing Properties of 1 ',5 '-Anhydro-L-Hexitol Nucleic Acids (L-HNA)(2009)
Authors: Arthur Van Aerschot, Jef Rozenski, Piet Herdewyn
Pages: 10121 - 10131 - Antibacterial 5 '-O-(N-dipeptidyl)-sulfamoyladenosines(2009)
Authors: Gaston Vondenhoff, Jef Rozenski, Jan Verhaegen, Arthur Van Aerschot, Piet Herdewyn
Pages: 260 - 269 - De novo approach to L-anhydrohexitol nucleosides as building blocks for the synthesis of L-hexitol nucleic acids (L-HNA)(2008)
Authors: Arthur Van Aerschot, Piet Herdewyn
Pages: 6068 - 6070